United Therapeutics extends Adcirca license with Lilly through Dec 2026

UNITED THERAPEUTICS Corp

Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.
Other terms of the license agreement remain unchanged.
Adcirca (tadalafil) is for treatment of pulmonary hypertension in the US.

item 8.01

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-121738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.